AMA004

AMA004 (also referred to as AMA-004) is an investigational gene therapy being developed by Amarna Therapeutics for the treatment of dry age-related macular degeneration (dAMD). The therapy utilizes Amarna's proprietary **Nimvec™** platform, which employs a non-immunogenic and tolerogenic viral vector derived from the Simian Virus 40 (SV40). AMA004 is designed to function as an immunomodulator, aiming to arrest chronic inflammation in the retina and stimulate the regeneration of retinal tissue to restore macular function. The program is currently in the preclinical stage and has received support through the Eurostars-funded HALT-AMD project to conduct proof-of-principle studies.